{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=12", "query": { "intervention": "Combination 600", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 472, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T07:56:47.329Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04395508", "title": "An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2022-07-05", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 12, "location_summary": "Beverly Hills, California • San Francisco, California • Stanford, California + 9 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04395508" }, { "nct_id": "NCT00877591", "title": "Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Dependency", "HIV Infections" ], "interventions": [ { "name": "Fosamprenavir/Ritonavir", "type": "DRUG" }, { "name": "Darunavir/Ritonavir", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Rifabutin", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-04", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-06", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877591" }, { "nct_id": "NCT01905813", "title": "Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Malignancies" ], "interventions": [ { "name": "INCB040093", "type": "DRUG" }, { "name": "INCB040093 + itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2013-06-30", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01905813" }, { "nct_id": "NCT02471846", "title": "A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "GDC-0919", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2015-07-28", "completion_date": "2019-10-02", "has_results": false, "last_update_posted_date": "2019-10-22", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471846" }, { "nct_id": "NCT01183169", "title": "Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 459, "start_date": "2010-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 18, "location_summary": "San Diego, California • Ventura, California • Bradenton, Florida + 13 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183169" }, { "nct_id": "NCT00141037", "title": "Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Diseases", "Kidney Transplantation", "Kidney Transplant", "Renal Transplantation", "Renal Transplant" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Trimethoprim and sulfamethoxazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 130, "start_date": "2004-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141037" }, { "nct_id": "NCT03944902", "title": "CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Resistant BRCA Wild-Type Ovarian Cancer" ], "interventions": [ { "name": "Cohort 1: Dose Escalation", "type": "DRUG" }, { "name": "Cohort 2: Dose Escalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2021-09-01", "completion_date": "2022-01-05", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 4, "location_summary": "Birmingham, Alabama • San Francisco, California • Rochester, Minnesota + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944902" }, { "nct_id": "NCT06088771", "title": "Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Dupilumab", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2024-10-09", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06088771" }, { "nct_id": "NCT01744912", "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-cell Lymphomas", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Waldenstrom's Macroglobulinemia" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-11-21", "completion_date": "2014-02-07", "has_results": false, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 2, "location_summary": "Huntsville, Alabama • Bethesda, Maryland", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01744912" }, { "nct_id": "NCT02052648", "title": "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Glioma", "Gliosarcoma", "Malignant Brain Tumor" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Stereotactic Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 160, "start_date": "2014-03", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-10-31T07:56:47.329Z", "location_count": 17, "location_summary": "Castro Valley, California • Los Angeles, California • Orange, California + 14 more", "locations": [ { "city": "Castro Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052648" } ] }